Physician profile
Steven M Fish
NPI 1760877120
$5,820.38
in general payments reported to CMS, 2019-2025
21 companies · $2,387 in 2025
The $2,387 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.08 · 2020: $773 · 2021: $620 · 2022: $1,590 · 2023: $139 · 2024: $298 · 2025: $2,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,650 · Food and Beverage: $1,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,650.00 |
| Food and Beverage | $1,174.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,869.93 | 2020-2025 | Idosetr, Istent Infinite, Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Allergan, INC. | $662.69 | 2020-2022 | |
| Abbvie INC. | $544.18 | 2022-2025 | |
| Alcon Vision LLC | $425.91 | 2020-2025 | Clareon, Tryptyr, Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $270.53 | 2021-2025 | Tecnis Simplicity |
| Sight Sciences, INC. | $208.04 | 2020-2025 | Omni Surgical System |
| Beaver-Visitec International, INC. | $124.99 | 2020-2023 | |
| Eyevance Pharmaceuticals LLC | $118.02 | 2021-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $112.56 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $105.11 | 2022-2024 | Xiidra, Miebo, Envista Mx60 Iol |
| New World Medical,INC. | $71.12 | 2022 | |
| Aerie Pharmaceuticals, INC. | $65.28 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $59.09 | 2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $42.08 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $32.51 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $27.70 | 2021-2022 | |
| Horizon Therapeutics Plc | $21.25 | 2022 | |
| Rxsight INC | $17.38 | 2025 | Rxsight Injector Handpiece, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Carl Zeiss Meditec USA, INC. | $15.38 | 2024 | Cirrus Hd-Oct |
| Sun Pharmaceutical Industries INC. | $13.55 | 2022 | |
| Alimera Sciences, INC. | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.